Drugs / SarcVac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07648069 | Sep 2024 → Dec 2026 expected | osteosarcoma, soft tissue sarcoma | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SarcVac | “The SarcVac peptide vaccine, mixed with an adjuvant (PolyI:C) in 0.5 ml of saline, is administered subcutaneously in the inguinal region on days 1, 3, 7, 15, 30, 65, and 86...” NCT07648069 ↗ |
| Modality | Vaccine | “The SarcVac peptide vaccine” NCT07648069 ↗ |
| Route | Subcutaneous | “is administered subcutaneously in the inguinal region” NCT07648069 ↗ |